CUMBERLAND PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
CPIX$5.30-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| 2025 | 2024 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(2,864,711) | $(6,443,715) |
| Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities: | ||
| Depreciation and amortization expense | 4,145,201 | 4,902,560 |
| Amortization of operating lease right-of-use asset | 1,140,738 | 1,140,738 |
| Loss on co-commercialization investment | 13,220 | — |
| Disposal of assets | — | 2,691 |
| Stock-based compensation | 408,320 | 301,895 |
| Increase (decrease) in non-cash contingent consideration | 46,569 | (1,460,804) |
| Increase in cash surrender value of life insurance policies over premiums paid | (142,927) | (139,953) |
| Noncash interest expense | 23,185 | 28,313 |
| Life insurance proceeds | — | (237,089) |
| Net changes in assets and liabilities affecting operating activities: | ||
| Accounts receivable | (5,243,314) | (1,943,290) |
| Inventories, net | 2,242,616 | 2,408,397 |
| Other current assets and other assets | (231,829) | 189,112 |
| Operating lease liabilities | (836,100) | 1,784,089 |
| Accounts payable and other current liabilities | 6,709,196 | (991,359) |
| Other long-term liabilities | (477,642) | (153,771) |
| Net cash provided by (used in) operating activities | 4,932,522 | (612,186) |
| Cash flows from investing activities: | ||
| Additions to property and equipment | (97,903) | (66,461) |
| Additions to intangible assets | (84,402) | (113,253) |
| Net investment in manufacturing | (2,477,192) | — |
| Other investment | (2,000,000) | — |
| Increase in cash surrender value of life insurance policies | (47,000) | — |
| Life insurance policy proceeds received | — | 237,556 |
| Net cash provided by (used in) investing activities | (4,706,497) | 57,842 |
| Cash flows from financing activities: | ||
| Borrowings on line of credit | — | 38,488,920 |
| Payments on line of credit | (10,035,437) | (35,996,894) |
| Proceeds from ATM offering, net | 5,266,334 | — |
| Payments made in connection with repurchase of common shares | (263,478) | (579,049) |
| Cash settlement of contingent consideration | (1,712,935) | (1,716,073) |
| Net cash provided by (used in) financing activities | (6,745,516) | 196,904 |
| Net decrease in cash and cash equivalents | (6,519,491) | (357,440) |
| Cash and cash equivalents, beginning of year | 17,964,184 | 18,321,624 |
| Cash and cash equivalents, end of year | $11,444,693 | $17,964,184 |
| 2025 | 2024 | |
|---|---|---|
| Supplemental disclosure of cash flow information: | ||
| Net cash paid during the year for: | ||
| Interest | $441,677 | $569,230 |
| State income taxes | (3,525) | 15,000 |
| Total cash paid included in measurement of lease liability | 836,100 | 863,320 |
| Noncash investing and financing activities: | ||
| Change in unpaid invoices for intangible asset additions | 4,727 | 530 |
| Change in unpaid invoices for offering costs | 62 | (69,701) |
| Lease liability obtained from right-of-use assets | 438,311 | 128,039 |
| Other investment liability | 2,000,000 | — |
See accompanying notes to consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.